WntResearch has granted patents within three patent families and four patent applications, three of which are in new patent families
The patent families relate to the company’s proprietary hexapeptide Foxy-5, Box-5 for the treatment of melanoma and Foxy-5 for the diagnosis and treatment of prostate cancer. WntResearch has four patent applications, three of which are in new patent families. These relate to the manufacturing method of the active drug substance Foxy-5 (2), Box-5 for the treatment of psoriasis, and the ability of Foxy-5 to reduce the number of cancer stem cells. Patent applications and granted patents are wholly owned by WntResearch AB. WntResearch is currently working on applications that could lead to another one or two patent applications within the Company’s business area.
Foxy-5 is patented in the US until 2028 and in the EU until 2026. In addition to patent protection, local authorities in many countries also offer extra protection in the form of market exclusivity for newly registered drugs. This means that Foxy-5 has exclusivity for at least eight years in the EU and up to seven years in the US, regardless of how long the patent time remains when registering the drug.
The company works actively to supplement the existing patent portfolio with new patent applications based on the company’s ongoing research and development. WntResearch has, therefore, recently filed a patent application regarding the manufacturing method for the active drug substance Foxy-5. Such a patent extends the effective term of protection of Foxy-5, both after the expiry of the original compound patent and the calculated market exclusivity, and thus, after granting, constitutes an obstacle to generic competition for a long time to come. For Box-5, a patent application has been filed for the treatment of psoriasis. The development of this therapeutic area will primarily take place through external research collaborations. In addition to investing in our own research programmes, the Company has recently taken over a patent application from an external inventor regarding the ability of Foxy-5 to reduce the number of cancer stem cells and the Company has thereby further strengthened the patent portfolio for Foxy-5.
Granted patents
| Patent family | Patent application no | Authority / Country | Priority | Expiration |
| A peptide ligand to impair cancer cell migration (Foxy-5) | 1 888 628; 2006 253056; 2 609 221; ZL200680019197.7; 4 942 745; 8 674 060; 60 2006 043 638.6; 502015902329163; 2 384 763; 60 2006 045 326.4; 284901; 502015000038251; 2 384 763; | All major markets, such as Europe, the US, India, China and Japan 2026 (those markets, excluding the US) 2028 (the US) | 2005-05-30 | 2026 (All markets except USA) 2028 (USA) |
| Treatment of melanoma (Box-5) | ZL200980129491.7; 502015902325866; 272 745; 5 583 668; 2 517 190; 8 497 352; 2 328 604; 60 2009 027 119.9; 2,733,636 | All major markets, such as Europe, the US, India, China and Japan | 2008-08-13 | 2029 |
| Treatment of prostate cancer and a method for determining the prognosis for prostate cancer patients | 9 278 119 | USA, EPC | 2011-07-01 | 2032 |
Pending patent applications
| Patent familiy | Patent application no | Authority / Country | Priority date | Expiration |
| Solution phase routes for Wnt hexapeptides | 18189699.4 | EPC | 2018-08-20 | 2038 |
| Wnt5a antagonist treatment in Psoriasis | 18193376.3 | EPC | 2018-09-10 | 2038 |
| Stem Cell Suppression | PCT/EP2018/079319 | PCT | 2017-10-25 | 2037 |
| Linear solution phase synthesis for Wnt hexapeptides | 18212658.1 | EPC | 2018-12-14 | 2038 |
